Related Experiment Video
Updated: Aug 22, 2026

Analysis of Interactions between Endobiotics and Human Gut Microbiota Using In Vitro Bath Fermentation Systems
Published on: August 23, 2019
Unveiling functional heterogeneity in pasteurized Akkermansia muciniphila identifies AKK2645 as a superior postbiotic
Yaqiong Li1, Wenfang Song2, Xiaoli Liu2
1Hunan Province Directly Affiliated TCM Hospital, Zhuzhou, China.
Abstract:
Metabolic syndrome (MetS) represents an escalating global health burden, underscoring an urgent need for innovative microbiome-targeted therapeutics. This investigation involved a systematic functional evaluation of 42 pasteurized Akkermansia muciniphila strains, providing the first direct evidence of significant differences among strains in their ability to alleviate MetS. Through systematic screening using cell and mouse models, we identified strain Akkermansia muciniphila YGMCC2645 (AKK2645) emerged as the lead candidate. Furthermore, it demonstrated superior and reproducible efficacy in attenuating diet-induced obesity, restoring glucose homeostasis, and ameliorating hepatic steatosis. AKK2645 uniquely modulated host immunity, decreasing pro-inflammatory cytokines (IL-6, IL-1β) and increasing anti-inflammatory markers (Il4, Il10, and Foxp3) in both adipose and hepatic tissues. It also favorably altered gut microbiota (increasing Akkermansia, Lactobacillus,and Bifidobacterium) and activated intestinal GLP-1 signaling. Collectively, these findings establish strain-specific functional heterogeneity as a fundamental principle governing postbiotic efficacy and identify AKK2645 as a high-potency, precision postbiotic for MetS intervention.
Insights
Akkermansia muciniphila strain AKK2645 effectively treats metabolic syndrome by improving gut health, reducing inflammation, and restoring metabolic balance. This precision postbiotic offers a promising new therapeutic avenue for this widespread condition.
Area of Science:
- Microbiology
- Immunology
- Metabolic Research
Background:
- Metabolic syndrome (MetS) is a growing global health concern requiring novel microbiome-based treatments.
- Significant heterogeneity exists among Akkermansia muciniphila strains regarding their therapeutic potential.
Purpose of the Study:
- To systematically evaluate 42 pasteurized Akkermansia muciniphila strains for their efficacy in alleviating MetS.
- To identify and characterize the most effective strain for MetS intervention.
Main Methods:
- Systematic functional screening of 42 Akkermansia muciniphila strains using cell and mouse models.
- Evaluation of strain AKK2645's efficacy in diet-induced obesity, glucose homeostasis, and hepatic steatosis models.
- Analysis of host immunity modulation, gut microbiota composition, and GLP-1 signaling.
Main Results:
- Strain Akkermansia muciniphila YGMCC2645 (AKK2645) demonstrated superior efficacy in attenuating obesity, improving glucose control, and reducing fatty liver.
- AKK2645 modulated host immunity by decreasing pro-inflammatory cytokines and increasing anti-inflammatory markers.
- AKK2645 favorably altered gut microbiota composition and activated intestinal GLP-1 signaling.
Conclusions:
- Strain-specific functional differences are crucial for postbiotic efficacy in treating MetS.
- Akkermansia muciniphila strain AKK2645 is identified as a potent, precision postbiotic for metabolic syndrome intervention.
Related Concept Videos
Probiotics
Dysbiosis of the Gut Microbiota
Functions of the Gut Microbiota
What is Monogastric Digestion?
Microbiota of the Stomach and Small Intestine
Microbiota Modulation by Antibiotics